We are live on ! Find out more
DCM

Driehaus Capital Management Portfolio holdings

AUM $13.6B
1-Year Est. Return 173.98%
This Fund
S&P 500
This Quarter Est. Return
+22.75%
1 Year Est. Return
+173.98%
3 Year Est. Return
+706.72%
5 Year Est. Return
+1,585.86%
10 Year Est. Return
+31,592.09%
AUM
$8.3B
AUM Growth
+$608M
Cap. Flow
-$511M
Cap. Flow %
-6.15%
Top 10 Hldgs %
19.18%
Holding
485
New
95
Increased
116
Reduced
139
Closed
106

Top Buys

Rank Stock Value
1
PDD icon
Pinduoduo
PDD
+$56.3M
2
TSM icon
TSMC
TSM
+$47.6M
3
WING icon
Wingstop
WING
+$41.3M
4
WAL icon
Western Alliance Bancorporation
WAL
+$39.5M
5
CAMT icon
Camtek
CAMT
+$38.8M

Top Sells

Rank Stock Value
1
ACLS icon
Axcelis
ACLS
+$78.8M
2
KNSL icon
Kinsale Capital Group
KNSL
+$71.8M
3
CELH icon
Celsius Holdings
CELH
+$68.7M
4
PCOR icon
Procore
PCOR
+$62.2M
5
TCOM icon
Trip.com Group
TCOM
+$50M

Sector Composition

Rank Sector Weight
1 Technology 23.03%
2 Industrials 21.11%
3 Healthcare 20.21%
4 Consumer Discretionary 8.72%
5 Financials 8.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAL icon
376
American Airlines Group
AAL
$10.1B
$193K ﹤0.01%
+14,079
New +$177K
ARCO icon
377
Arcos Dorados Holdings
ARCO
$1.72B
$182K ﹤0.01%
+14,364
New +$154K
CLDI icon
378
Calidi Biotherapeutics
CLDI
$1.98M
$143K ﹤0.01%
49
TH icon
379
CALL
Target Hospitality
TH
$1.51B
$20K ﹤0.01%
400,000
ACLS icon
380
Axcelis
ACLS
$4.01B
-483,526
Closed -$78.8M
ACMR icon
381
ACM Research
ACMR
$5.42B
-76,712
Closed -$1.39M
APO icon
382
Apollo Global Management
APO
$72.4B
-2,639
Closed -$237K
ARRY icon
383
Array Technologies
ARRY
$803M
-520,682
Closed -$11.6M
ATKR icon
384
Atkore
ATKR
$2.46B
-130,232
Closed -$19.4M
ATRA icon
385
Atara Biotherapeutics
ATRA
$75.5M
-23,598
Closed -$873K
BAP icon
386
Credicorp
BAP
$31.8B
-257,156
Closed -$32.9M
BDX icon
387
Becton Dickinson
BDX
$45.6B
-2,377
Closed -$615K
BIDU icon
388
Baidu
BIDU
$37.7B
-227,443
Closed -$30.6M
BILL icon
389
BILL Holdings
BILL
$4.49B
-83,681
Closed -$9.09M
BSX icon
390
Boston Scientific
BSX
$69.5B
-9,396
Closed -$496K
BTAI icon
391
BioXcel Therapeutics
BTAI
$24.9M
-1,389
Closed -$56.2K
CACI icon
392
CACI
CACI
$11B
-24,377
Closed -$7.65M
DGII icon
393
Digi International
DGII
$2.63B
-706,681
Closed -$19.1M
EB
394
DELISTED
Eventbrite
EB
-1,163,153
Closed -$11.5M
FOCL
395
EDAP TMS S.A.
FOCL
$229M
-694,358
Closed -$4.87M
EG icon
396
Everest Group
EG
$14.5B
-19,503
Closed -$7.25M
ERII icon
397
Energy Recovery
ERII
$446M
-546,780
Closed -$11.6M
ESAB icon
398
ESAB
ESAB
$5.38B
-274,012
Closed -$19.2M
ESTA icon
399
Establishment Labs
ESTA
$2.72B
-153,391
Closed -$7.53M
ETNB
400
DELISTED
89bio
ETNB
-432,174
Closed -$6.67M

Similar funds

Driehaus Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Driehaus Capital Management held 485 positions worth $8.3B, up 7.9% from $7.69B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Driehaus Capital Management withdrew a net $511M in Q4 2023, closing 106 positions and reducing 139 holdings. Its most notable exit was Axcelis, an estimated $78.8M position sold in full.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Industrials and Healthcare.

Against the trend, Driehaus Capital Management opened a new position in Pinduoduo worth $67.9M.

  • Driehaus Capital Management's largest Q4 2023 buy was Pinduoduo: 463,956 shares worth $67.9M.
  • Driehaus Capital Management added most to TSMC in Q4 2023, an estimated $47.6M increase.
  • Driehaus Capital Management's biggest Q4 2023 reduction was Kinsale Capital Group, cutting an estimated $71.8M.
  • Driehaus Capital Management fully exited Axcelis in Q4 2023, selling an estimated $78.8M.
  • Driehaus Capital Management's ten largest holdings make up 19% of its $8.3B portfolio in Q4 2023.
  • Driehaus Capital Management opened 95 new positions and closed 106 in Q4 2023.
  • Driehaus Capital Management's portfolio value rose 7.9% quarter-over-quarter to $8.3B.

Based on Driehaus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.